Cipla News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Cipla Ltd. authored by Geojit BNP Paribas and published by - Trendlyne research reports.
Item: Cipla Ltd.
Rating: 3
Author: Geojit BNP Paribas

Keep track of all breaking news and updates on Cipla from all sources in a single place.

Cipla Ltd.

30 Dec 2025, 03:12PM

1492.50

-0.10%

Company Update

Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Change in Management

BSE India

Superannuation of Senior Management Personnel on 31st December 2025

pdf

Cipla Ltd.

23 Dec 2025

1492.50

-0.10%

Board Meeting

Cipla Ltd - 500087 - Board Meeting Intimation for Meeting Of The Board Of Directors Of …

BSE India

Cipla Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/01/2026 ,inter alia, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended 31st December, 2025.

pdf

Cipla Ltd.

23 Dec 2025

1492.50

-0.10%

CIPLA LTD

Hold: Cipla Ltd.

Recommendation Target

Geojit BNP Paribas

Cipla Ltd delivered a steady Q2FY26 performance, supported by strong branded generics in India and continued leadership in its US respiratory business (albuterol MDI). The company's strategic focus on high-growth therapies such as obesity and diabetes (exclusive launch of Tirzepatide Yurpeak in India) underpins its long-term growth potential. However, near-term challenges remain, including the anticipated revenue erosion from the Revlimid cliff, increased R&D intensity weighing on margins, and execution risk related to timely approvals, which could limit earnings visibility and margin recovery in the medium term, thereby warranting a more...

Geojit BNP Paribas downgraded Cipla Ltd. to Hold with a price target of 1645.0 on 23 Dec, 2025.

Cipla Ltd.

22 Dec 2025

1492.50

-0.10%

Cipla launches inhaled insulin', a needle-free alternative for people with diabetes

Business Line

Cipla Ltd. is trading below all available SMAs

Cipla Launches Inhalable Insulin For Diabetes Care

NDTV Profit | 22 Dec 2025 1 more

Cipla Ltd.

22 Dec 2025

1492.50

-0.10%

Company Update

Cipla Ltd - 500087 - Intimation Under Regulation 30 Read With Schedule III Of The SEBI …

BSE India

Please find attached disclosure on ESG rating

pdf

Cipla Ltd.

19 Dec 2025

1492.50

-0.10%

Cipla to exclusively market and distribute five Pfizer brands in India

Business Standard

Cipla will exclusively market five Pfizer brands in India, adding 400-430 crore of established acute therapies to its portfolio without manufacturing risk

Cipla Ltd. has an average target of 1697.44 from 9 brokers.

Cipla ties up with Pfizer for exclusive marketing of four brands

livemint | 19 Dec 2025

Cipla Ltd.

19 Dec 2025

1492.50

-0.10%

Company Update

Cipla Ltd - 500087 - Cipla Limited Has Entered Into Exclusive Supply And Marketing Agreement For …

BSE India

Cipla Limited has informed the exchange that it has entered into an exclusive supply and marketing agreement with Pfizer''s brands

pdf

Cipla Ltd.

17 Dec 2025

1492.50

-0.10%

Company Update

Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

BSE India

In compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby notify that the Operations and Administrative Committee of the Company on 17th December, 2025 has allotted 585 fully paid up equity shares of INR 2 each, pursuant to exercise of employee stock options/stock appreciations rights under the Employee Stock Option Scheme 2013-A and Cipla Employee Stock Appreciation Rights Scheme 2021 of the Company.

pdf